School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Vertex Pharmaceuticals Incorporated VRTX

Healthcare · Biotechnology

$510.08last close 2026-10-09 · market cap $129.20B · delayed data

Trailing returns

1M-2.12%
3M+2.74%
6M+14.17%
1Y+22.95%
5Y+185.06%

Basis: Adjusted daily closes.

What it does

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.

Open VRTX in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies